What is Kuros Biosciences AG (CSBTF)?

Kuros Biosciences AG (CSBTF) is a stock in the Healthcare sector, Medical - Devices industry. View full analysis on Stocks360.

What is the current price of CSBTF?

The current price of CSBTF is $23.00. Prices are updated in real time on Stocks360.

What is CSBTF's price-to-earnings (PE) ratio?

CSBTF's trailing twelve-month PE ratio is 115.14, based on current price and earnings per share data available on Stocks360.

What is CSBTF's market capitalization?

CSBTF's market capitalization is $914,404,008.00, placing it in the small-cap tier.

Kuros Biosciences AG (CSBTF)

Stock analysis · OTC · Healthcare · Medical - Devices

$23.00

Market Cap

$914.40M

PE (TTM)

115.14

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.76

Day Range

$23.00 – $23.00

52-wk Range

$22.00 – $38.91

Avg Volume

N/A

Volume

100.00

Kuros Biosciences AG (CSBTF) is a publicly traded company in the Healthcare sector. Latest price: $23.00. Market cap $914.40M. Trailing PE 115.14. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 18, 2021

EPS $-0.34 vs est. $-0.34

Beat by $0.00

Next Earnings

Mar 3, 2027

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Kuros Biosciences AG

Kuros Biosciences AG, a biopharmaceutical firm headquartered in Schlieren, Switzerland, specializes in both bringing to market and advancing therapeutic solutions for tissue repair and bone regeneration. Its global reach extends across the United States, the European Union, and other international markets, with operations strategically divided into Medical Devices, Pharmaceuticals, and a Legacy Portfolio. The company's innovative product lineup includes several key orthobiologics. Their MagnetOs Granules and MagnetOs Putty are already available in the EU and US, serving applications in orthopedics, spinal procedures, and dentistry. Additionally, their fibrin/PTH orthobiologics portfolio features KUR-111, which has successfully concluded Phase 2b clinical trials for treating tibial plateau fractures, and KUR-113, which completed Phase 2b trials for tibial shaft fractures and is currently in Phase II development for spinal interbody fusion. Beyond bone healing, Kuros Biosciences provides advanced sealant solutions, such as Neuroseal, a synthetic tissue sealant approved in the EU and US for preventing cerebrospinal fluid leakage after cranial or spinal surgeries. The company also fos…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	115.14×
P/S (TTM)	5.97×
P/B	11.42×
PEG	0.13×
P/FCF (TTM)	-125.29×
EV / EBITDA	71.98×
EV / Sales	6.00×
Earnings Yield	0.87%
Free Cash Flow Yield	-0.80%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$831.69M
Revenue (TTM)	$138.71M
Net Income (TTM)	$7.17M
Free Cash Flow (TTM)	-$5.05M
Net Debt	$3.16M
Working Capital	$31.25M
Gross Margin	85.28%
Operating Margin	6.01%
Net Margin	5.13%
Return on Equity	10.24%
Return on Invested Capital	8.03%